



ORIGINAL ARTICLE

Detection of toxigenic *Clostridioides* [*Clostridium*] *difficile*: Usefulness of two commercially available enzyme immunoassays and a PCR assay on stool samples and stool isolates



María C. Legaria^{a,b,*}, Raquel Rollet^{a,c}, Ana Di Martino^{a,d}, Liliana Castello^{a,e},
Claudia Barberis^{a,f}, María A. Rossetti^{a,g}, María C. Guardati^{a,h},
Liliana Fernández Canigia^{a,i}, Graciela Carloni^{a,j}, Mirta Litterio^{a,k}, Marta Rocchi^l,
Eduardo G. Anchart^m, Fernando M. Trejoⁿ, Jessica Minnaardⁿ, Diana Klajn^b,
Silvia C. Predari^{a,e}

^a Subcomisión de Bacterias Anaerobias de la Sociedad Argentina de Bacteriología, Micología y Parasitología Clínicas – Asociación Argentina de Microbiología, Ciudad Autónoma de Buenos Aires (CABA), Argentina

^b Hospital General de Agudos Dr. Enrique Tornú, CABA, Argentina

^c Hospital de Infecciosas Dr. Francisco Javier Muñiz, CABA, Argentina

^d Sanatorio de la Trinidad Mitre, CABA, Argentina

^e Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, CABA, Argentina

^f Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, CABA, Argentina

^g Hospital Interzonal General de Agudos Presidente Perón, Avellaneda, Provincia de Buenos Aires, Argentina

^h Hospital de Emergencias Dr. Clemente Álvarez, Rosario, Provincia de Santa Fe, Argentina

ⁱ Hospital Alemán, CABA, Argentina

^j Facultad de Ciencias Veterinarias, Universidad de Buenos Aires, CABA, Argentina

^k Hospital Nacional de Pediatría Dr. Prof. Juan P. Garrahan, CABA, Argentina

^l Hospital Nacional de Clínicas de Córdoba, Córdoba, Argentina

^m Centro de Especialidades Médicas Ambulatorias de Rosario MH Zuasnábar (Cemar), Secretaría de Salud Pública de Rosario, Provincia de Santa Fe, Argentina

ⁿ Centro de Investigación y Desarrollo en Criotecología de Alimentos (CIDCA) – Cátedra de Microbiología Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Provincia de Buenos Aires, Argentina

Received 8 June 2016; accepted 13 January 2017

Available online 6 October 2017

KEYWORDS

Clostridioides
[Clostridium] difficile

Abstract The best laboratory diagnostic approach to detect *Clostridioides* [*Clostridium*] *difficile* infection (CDI) is a subject of ongoing debate. With the aim of evaluating four laboratory diagnostic methods, 250 unformed stools from patients with suspected CDI submitted to nine medical center laboratories from November 2010 to December 2011, were studied using: (1) an immunochromatographic rapid assay test that combines the qualitative determination of

* Corresponding author.

E-mail address: mclegaria@hotmail.com (M.C. Legaria).

Clostridioides [Clostridium] difficile infection;
CDI diagnosis

glutamate dehydrogenase (GDH) plus toxins A and B (QAB), the CDIFF QUIK CHEK COMPLETE assay; (2) an enzyme immunoassay for qualitative determination of toxins A and B, the RIDASCREEN™ *C. difficile* Toxin A/B assay (RAB); (3) a PCR for the toxin B gene assay (PCR); and (4) the toxigenic culture (TC). *C. difficile* isolates from direct toxin negative stools by QAB, RAB and PCR were evaluated for toxigenicity by the same direct tests, in order to assess the contribution of the TC (QAB-TC, RAB-TC, PCR-TC). A combination of the cell culture cytotoxicity neutralization assay (CCCNA) in stools, and the same assay on isolates from direct negative samples (CCCNA-TC) was considered the reference method (CCCNA/CCCNA-TC). Of the 250 stools tested, 107 (42.8%) were positive by CCCNA/CCCNA-TC. The GDH and PCR/PCR-TC assays were the most sensitive, 91.59% and 87.62%, respectively. The QAB, RAB, QAB/QAB-TC and RAB/RAB-TC had the highest specificities, ca. 95%. A negative GDH result would rule out CDI, however, its low positive likelihood ratio (PLR) of 3.97 indicates that a positive result should always be complemented with the detection of toxins. If the RAB, QAB, and PCR assays do not detect toxins from direct feces, the toxigenic culture should be performed. In view of our results, the most accurate and reliable methods to be applied in a clinical microbiology laboratory were the QAB/QAB-TC, and RAB/RAB-TC, with PLRs >10 and negative likelihood ratios <0.30.

© 2017 Asociación Argentina de Microbiología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALABRAS CLAVE

Clostridioides [Clostridium] difficile;
Infección causada por *Clostridioides [Clostridium] difficile*;
Diagnóstico de ICD

Detección de *Clostridioides [Clostridium] difficile* toxigénico: utilidad de dos métodos de enzoinmunoensayo comerciales y una PCR en las muestras de materia fecal y en los respectivos aislamientos

Resumen El mejor procedimiento para realizar el diagnóstico de laboratorio de la infección causada por *Clostridioides [Clostridium] difficile* (ICD) es aún objeto de debate. Con el fin de evaluar cuatro métodos diagnósticos de laboratorio, se estudiaron 250 muestras de heces diarreicas provenientes de pacientes con sospecha de ICD remitidas a los laboratorios de nueve centros médicos entre noviembre de 2010 y diciembre de 2011. Dichas muestras se analizaron mediante los siguientes métodos: 1) un ensayo rápido inmunocromatográfico que combina la detección cualitativa de la glutamato deshidrogenasa (GDH) y de las toxinas A y B (QAB), CDIFF QUIK CHEK COMPLETE; 2) un enzoinmunoanálisis para la determinación cualitativa de las toxinas A/B, RIDASCREEN™ *C. difficile* Toxin A/B (RAB); 3) un método molecular basado en PCR para la detección del gen que codifica la toxina B (PCR) y 4) el cultivo toxigénico (TC). Como método de referencia se utilizó la combinación del ensayo de citotoxicidad sobre cultivo de células con la neutralización de toxina mediante anticuerpo específico en los filtrados de las heces (CCCNA) y el mismo método en sobrenadantes de aislamientos de *C. difficile* (CCCNA-TC). La toxigenicidad de las cepas aisladas de muestras directas negativas con QAB, RAB y PCR se evaluó con los mismos métodos, con el propósito de detectar la contribución del TC (QAB-TC, RAB-TC, PCR-TC). De las 250 muestras estudiadas, 107 (42,8%) fueron positivas por CCCNA/CCCNA-TC. Los métodos GDH y PCR/PCR-TC fueron los más sensibles: 91,59 y 87,62%, respectivamente. Los métodos QAB, RAB, QAB/QAB-TC y RAB/RAB-TC mostraron las mayores especificidades, del 95%, aproximadamente. Un resultado negativo para GDH excluiría la ICD, pero su baja razón de verosimilitud positiva (PLR), que fue 3,97, indica que un resultado positivo debe complementarse con la detección de toxinas. Cuando no se detectan toxinas directas por RAB, QAB ni PCR, debería realizarse el TC. De acuerdo con nuestros resultados, los métodos más precisos y confiables para ser aplicados en un laboratorio de microbiología clínica son QAB/QAB-TC y RAB/RAB-TC, con una PLR > 10 y una razón de verosimilitud negativa < 0,30.

© 2017 Asociación Argentina de Microbiología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Clostridioides [Clostridium] difficile is increasingly recognized as an important nosocomial pathogen with significant

morbidity and mortality. *C. difficile* infection (CDI) is a serious healthcare concern, with high incidence and recurrence rates, healthcare costs, and which is sometimes refractory to standard treatment^{3,9,22,23,38,43,56,57}.

C. difficile is known to express up to three toxins: toxin A (TcdA), toxin B (TcdB), and 6–12.5% of strains produce a third toxin called binary toxin (CDT). These toxins cause extensive colonic inflammation, epithelial tissue damage, and cell death. CDI shows a wide spectrum of clinical manifestations, from a mild, self-limited diarrheal illness to a fulminant, life-threatening colitis and recurrence. Its acquisition is mostly related to hospital or healthcare, however, it can also be observed in outpatients. Moreover, it is important to note that community-associated CDI (CA-CDI) may occur in individuals who lack the traditional risk factors such as antibiotic use, advanced age, and severe underlying disease^{8,30,68}. In the past decade, the epidemiology of *C. difficile* changed and new types have emerged^{7,23}.

C. difficile is genetically heterogeneous, as well as its geographical distribution. Outbreaks related to strains that produce the binary toxin, called “hypervirulent” types (ribotype 027 and ribotype 078), have been detected in some countries and associated with more severe disease. The 027/NAP1/BI strain also carries an 18-bp deletion and a 1-bp deletion (at nucleotide [nt] 117) in the *tcdC* gene, a putative negative regulator of *tcdA* and *tcdB* gene expression^{1,8,28}. Several pathogenic TcdA-negative, TcdB-positive strains that have been found in Asia and Latin America – including Argentina – may affect the CDI diagnosis depending on the kind of tests performed^{5,14,16,29,34,37,39–41,44}.

The best laboratory diagnostic approach to detect CDI is a subject of ongoing debate^{4,25,67}.

Since *C. difficile* colonization or infection cannot be distinguished by laboratory testing, toxin detection should be performed only in symptomatic patients. It consists of detecting toxigenic *C. difficile* or its toxins A and B in unformed stools, when illness due to *C. difficile* is suspected⁴. Historically, the cell culture cytotoxicity neutralization assay (CCCNA) was considered the gold standard method for the diagnosis of CDI. However, many laboratories do not have the technical expertise, facilities or training to perform it. In addition, it requires at least 16 h to obtain the result. Toxins A/B enzyme immunoassay (EIA) is the most widely used test for the detection of *C. difficile* TcdA and TcdB, but it is associated with poor sensitivity, thus with an unacceptable high rate of false-negative results^{20,47,55}.

Polymerase chain reaction (PCR), nested PCR and real-time PCR have been found to be effective for the detection of toxin genes in stool specimens, with good sensitivity and specificity^{13,15,24,33,36,50,63}.

The detection of toxigenic strains of *C. difficile* is currently a more sensitive approach for the diagnosis of CDI; however, the culture is infrequently done for diagnostic purposes because of its slow turnaround time, the need for special isolation media and technical expertise. On the other hand, the toxigenic culture (TC) is recommended as the gold standard method because it is the best performing test available. Indeed, it shows better sensitivity (90–100%), and specificity (98–100%) than the traditionally used CCCNA (70–100% and 90–100%, respectively). Moreover, TC is essential for further epidemiological and susceptibility studies^{12,46,54}.

On the other hand, the glutamate dehydrogenase (GDH) assay, which detects the antigen present in both toxigenic and nontoxigenic strains of *C. difficile*, and directly in stool samples, is simple, rapid and appears to have good

sensitivity. However, it lacks specificity, and like the culture, needs to be followed by toxin detection^{26,58–60}.

The use of the GDH assay as screening and the confirmation of its positive results with the detection of TcdA and TcdB by EIA, TC or CCCNA seems to be the best algorithm to perform in laboratories. The nucleic acid amplification tests, especially PCR assay for the detection of *C. difficile* toxin B gene (*tcdB*), have emerged as an option of a multitest algorithm^{12,35}.

The purpose of this study was to assess the usefulness of four available laboratory methods for the diagnosis of CDI. An immunochromatographic rapid assay test that combines the qualitative determination of toxins A and B of *C. difficile* plus GDH in stool samples, an enzyme immunoassay for the qualitative determination of *C. difficile* toxins A and B in human stool specimens, a PCR assay to detect the *tcdB* toxin gene of *C. difficile*, and the toxigenic culture were performed. The combination of a direct cytotoxicity assay from stool samples and the cytotoxicity assay from stool isolates results was considered the gold standard method.

Materials and methods

From November 2010 to December 2011, 250 unformed fecal samples of adult patients at risk of CDI were provided for the study by the following laboratories (n;%): Sanatorio de la Trinidad Mitre, Ciudad Autónoma de Buenos Aires (CABA) (49; 19.6); Hospital General de Agudos Dr. Enrique Tornú, CABA (34; 13.6); Instituto de Investigaciones Médicas Alfredo Lanari – Universidad de Buenos Aires, CABA (30; 12); Hospital de Clínicas José de San Martín – Universidad de Buenos Aires, CABA (30; 12); Hospital de Infecciosas Dr. Francisco J. Muñoz, CABA (25; 10); Hospital Nacional de Clínicas de Córdoba, Córdoba (25; 10); Hospital Interzonal General de Agudos Presidente Perón, Avellaneda, Provincia de Buenos Aires (20; 8); Hospital de Emergencias Clemente Álvarez, Rosario (HECA), Provincia de Santa Fe (20; 8); and Hospital Alemán, CABA (17; 6.4). Stool specimens were submitted in sterile containers and stored at 4 °C up to 24 h. Prior to process, samples were mixed well and split using a sterile disposable graduated pipette. A 0.5 ml aliquot of stool specimen was transferred from the original collection container to a sterile cryovial and frozen at –20 °C for further PCR. A 1 ml aliquot of stool was added to 1 ml of saline solution (NaCl 0.085 g/l), homogenized vigorously and centrifuged at 3000 × g for 15 min. The supernatant was filtered through a 0.45 µm membrane and the fecal filtrate was transferred to a cryovial and frozen at –20 °C for further CCCNA. A 0.5 ml aliquot was used for the enzyme immunoassays, and a 0.5–1 ml aliquot of stool sample was transferred to a sterile glass test tube for culture. Stool specimens were tested by QAB, RAB, PCR and CCCNA. An ethanolic shock was performed prior to the stool culture. The toxigenic isolates were characterized using standard phenotypic methods⁶¹.

C. difficile colonies were suspended in brain heart infusion (BHI) broth (Britania™, Argentina) and incubated in anaerobic conditions. An aliquot was centrifuged for 5 min at 13 000 × g and cell free supernatants (CFS) were obtained by filtration as described below for further CCCNA-TC.

In order to assess the contribution of the TC, *C. difficile* isolates from toxin-negative stool specimens by

QAB, RAB, PCR and CCCNA were tested for toxigenicity by the same direct tests named QAB-TC, RAB-TC, PCR-TC, and CCCNA-TC. The combination of toxin detection results in supernatants from stool specimens (CCCNA) and from isolates (CCCNA-TC) was used as the reference test (CCCNA/CCCNA-TC).

Combination testing – GDH detection and toxin EIA. C DIFF QUIK CHEK COMPLETE™ (Techlab, Inc., USA)

It is a rapid cassette membrane enzyme immunoassay for the simultaneous detection of the GDH antigen and TcdA and TcdB of *C. difficile* in fecal specimens. Testing was performed on stool samples and their isolates according to the manufacturer's recommendations. The C Diff Quik Chek Complete test detects the GDH antigen of *C. difficile* and toxins A and B, without differentiation of the toxins. With the purpose of providing most useful information of the results of the GDH assay alone, we evaluated its detection independently (Table 1).

RIDASCREEN™ *Clostridium difficile* Toxin A/B (R-Biopharm AG, Germany)

It is an EIA for the qualitative determination of the *C. difficile* toxins A/B in stool specimens and from cultures of toxin-producing *C. difficile* strains. The test was performed according to the manufacturer's instructions on stool specimens and stool isolates.

Cell-culture cytotoxicity neutralization assay

Fecal filtrates and CFS were stored at -20°C until CCCNA/CCCNA-TC were performed. Cell cultures: Vero cells were grown in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL Life Technologies, Rockville, MD, USA) supplemented with 10% (v/v) inactivated fetal calf serum (30 min, 60°C) (BIOSER, Argentina, PAA Laboratories GmbH), 2 g NaCO_3H , streptomycin 10 mg/l and penicillin G 10 IU/ml. Cells (4×10^4 cells per well) were inoculated in 96-well tissue culture plates (Corning, NY, USA) and incubated at 37°C for 48 h in a 5% CO_2 /95% air atmosphere. Cytotoxicity assay: cultured cells were washed twice with 0.2 ml of phosphate-buffered saline (PBS; KH_2PO_4 0.144 g/l, NaCl 9 g/l, Na_2HPO_4 0.795 g/l, pH 7.5). One hundred microliters of two-fold dilutions of fecal filtrates or CFS in DMEM (without fetal calf serum) were added per well and incubated at 37°C for 16 h in a 5% CO_2 /95% air atmosphere. Biological activity through determination of cytopathic effects (cell rounding) was evaluated by microscopy. Positive samples were confirmed when cytopathic effect was neutralized in the presence of anti-TcdB monoclonal antibody (Meridian Life Science, Inc., USA). The titer of biological activity was defined as 1/(sample dilution) that produces rounding on 100% of cells^{45,62,67}.

Polymerase chain reaction

The PCR was performed in previously frozen fecal samples and suspensions of isolates in sterile distilled water stored

at -20°C . DNA was extracted from 200 mg of the stool by using QIAamp DNA Stool Kit (Qiagen, Germany) according to the manufacturer's recommendations. The final volume of the DNA extract was 200 μl . DNA was extracted from 2 to 3 *C. difficile* colonies that were suspended in ultrapure distilled water, then boiled for 10 min and centrifuged at $15000 \times g$ for 2 min. PCRs were carried out in 25 μl of volume reaction, where 6.25 μl of the extract was added to 18.75 μl of the reaction mix consisting of: 2.5 mM MgCl_2 , 50 mM KCl, 10 mM Tris-HCl (pH 9.0), the four deoxynucleoside triphosphates (0.075 mM of each other), 0.4 μM of each primer, and 0.05 U/ μl of *Taq* DNA polymerase. A segment of the *tcdB* gene was amplified by using primer NK104-sequence 5'-GTGTAGCAATGAAAGTCCAAGTTTACGC-3'; positions 2945 to 2972- and primer NK105 -sequence 5'-CACTTAGCTCTTTGATTGCTGCACCT-3'; positions 3123 to 3148-, which were derived from the nonrepeating sequence of the *tcdB* gene of *C. difficile*^{32,64}. The thermal profile was one cycle at 95°C for 4 min followed by 35 cycles comprising one step at 95°C for 20 s, 60°C for 20 s and 72°C for 20 s. At the end of the PCR cycles, the tubes were incubated at 72°C for 7 min. The presence of a 204-bp fragment was considered indicative of the presence of the *tcdB* gene. The amplified product was analyzed until separation by electrophoresis on 2% agarose gel with ethidium bromide. A positive control of pure DNA from toxigenic *C. difficile* strain ATCC 43255, a negative control of pure DNA from a clinical isolate of *Clostridium sordellii*, and sterile distilled water were added to each run. For the detection of inhibitors, 2 μl of each eluate extracted from all PCR-negative samples was spiked with 2 μl of the eluate from a PCR-positive stool.

Ethanol shock of stools and cytotoxigenic cultures

All stool specimens were subjected to ethanolic shock with 1:1 vol/vol absolute ethanol/stool sample, mixed and incubated for 30 min at room temperature. Then, they were cultured on brain heart infusion agar (BHIA) supplemented with 5% lysed horse blood, and on BHIA with 16 mg/l of cefoxitin (BHIAc). Plates were incubated anaerobically at 37°C and examined after 48–72 h. Gray-white colonies with irregular filamentous edges or opaque appearance on BHIA or BHIAc plates, morphologically resembling *C. difficile*, were Gram-stained. If suspicious for *Clostridium* spp., they were subcultured onto Brucella blood agar plates (Britania™) and also tested for aerotolerance on chocolate agar plates (Britania™) in a 5% CO_2 atmosphere. *C. difficile* was identified by no growth at 37°C after 48–72 h of incubation under 5% CO_2 , a positive result for the proline aminopeptidase test, gelatin and esculin hydrolysis, a negative result for indole, lecithinase and lipase production, and having a characteristic "horse barn" odor. *C. difficile* isolates that grew on BHIAc or BHIA from toxin-negative stool samples were tested for toxigenicity. Isolates were inoculated into BHI broth and incubated in anaerobic conditions. They were centrifuged at $3000 \times g$ for 10 min, and the supernatants were tested by the same direct methods CCCNA, EIAs, and PCR.

Table 1 Comparison of *Clostridioides [Clostridium] difficile* diagnostic testing directly from stool samples and from the stool isolates, against the results of the combination of CCCNA/CCCNA-TC

Method	Sensitivity (%) (95% CI) ^a	Specificity (%) (95% CI) ^a	PPV (%) ^b (95% CI) ^a	NPV (%) ^b (95% CI) ^a	PLR ^c (95% CI) ^a	NLR ^c (95% CI) ^a
GDH ^d	91.59 (85.86–97.32)	76.92 (69.67–84.18)	74.81 (66.99–82.62)	92.44 (87.27–97.61)	3.97 (2.93–5.38)	0.11 (0.06–0.21)
RAB ^e	52.94 (42.76–63.12)	96.62 (93.37–99.87)	91.53 (83.57–99.48)	74.87 (68.46–81.28)	15.67 (6.49–37.81)	0.49 (0.40–0.60)
RAB/RAB-TC ^e	74.53 (65.76–83.29)	95.07 (91.16–98.98)	91.86 (85.50–98.22)	83.33 (77.29–89.38)	15.12 (7.28–31.40)	0.27 (0.19–0.37)
QAB ^f	58.88 (49.09–68.67)	94.41 (90.29–98.52)	88.73 (80.67–96.79)	75.42 (68.83–82.01)	10.52 (5.27–21.02)	0.44 (0.35–0.55)
QAB/QAB-TC ^f	78.30 (69.98–86.62)	94.41 (90.29–98.52)	91.21 (84.84–97.18)	85.44 (79.63–91.26)	14.00 (7.09–27.65)	0.23 (0.16–0.33)
PCR ^g	77.14 (68.63–85.65)	82.52 (75.94–89.09)	76.42 (67.86–84.97)	83.10 (76.58–89.61)	4.41 (3.04–6.39)	0.28 (0.19–0.40)
PCR/PCR-TC ^g	87.62 (80.84–94.40)	83.92 (77.55–90.29)	80.00 (72.25–87.75)	90.23 (84.80–95.65)	5.45 (3.72–7.98)	0.15 (0.09–0.25)

^a 95% CI: 95% confidence interval.

^b PPV/NPV: positive/negative predictive value.

^c PLR/NLR: positive/negative likelihood ratio.

^d GDH: Quik Chek glutamate dehydrogenase in a stool specimen.

^e RAB/RAB-TC: Ridascreen toxin A + B in stool specimen/in stool specimen plus toxigenic culture.

^f QAB/QAB-TC: Quik Chek toxin A + B, in stool specimen/in stool specimen plus toxigenic culture.

^g PCR/PCR-TC: *tcdB* in stool specimen/in stool specimen plus toxigenic culture.

Statistical analysis

Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR) and negative likelihood ratio (NLR) with their corresponding 95% confidence intervals were calculated for all the assays. Because PPVs and NPVs depend on the prevalence of *C. difficile*, we evaluated the clinical diagnostic value of the different tests by comparing the results obtained with the likelihood ratios (NLR and PLR) to become independent of those parameters. All parameters were estimated and analyzed by the SPSS Statistics version 20.0 software (SPSS, Inc., Chicago, IL).

Results

Of the 250 fecal samples studied, 107 (42.8%) were positive by CCCNA/CCCNA-TC.

The performance of the GDH, QAB, RAB, and PCR assays in stools, and the QAB-TC, RAB-TC and PCR-TC assays on isolates was assessed as follows: all 250 samples were tested by the RAB, QAB, and GDH assays; 249 samples were available to be tested using the QAB-TC, 248 using RAB-TC and PCR-TC, and 247 by PCR assays.

The results of each method were compared against the results of the CCCNA/CCCNA-TC combination. Sensitivity, specificity, PPV, NPV, PLR, and NLR of the GDH, QAB, RAB, PCR, QAB/QAB-TC, RAB/RAB-TC and PCR/PCR-TC assays and their 95% confidence interval are summarized in [Table 1](#), which shows the results of the comparison of *C. difficile* detection methods with the results of the gold standard CCCNA/CCCNA-TC.

The highest sensitivities and NPVs were found with GDH and PCR/PCR-TC, approximately 90% with both methods. Specificities and PPVs were high, approximately 95% and approximately 90% with RAB, RAB/RAB-TC, QAB, and QAB/QAB-TC, respectively.

Of the 107 positive samples by the gold standard, 47 (43.93%) and 7 (6.54%) specimens were determined to be positive and negative by all assays, respectively. The GDH and PCR were the only positive tests in 6/107 (5.6%), and 1/107 (0.9%) positive samples, respectively.

Accordingly, RAB, RAB/RAB-TC, QAB and QAB/QAB-TC assays with PLRs >10, and GDH, PCR/PCR-TC, PCR, QAB/QAB-TC and RAB/RAB-TC assays with NLRs <0.30 demonstrated to be useful to be applied in a clinical microbiology laboratory; however, the most accurate and reliable methods for diagnosis of CDI proved to be the QAB/QAB-TC or RAB/RAB-TC with both, PLRs >10 and NLRs <0.30.

Discussion

Despite the availability of several laboratory methods to diagnose CDI, the optimal strategy is debatable⁶. The guidelines recommend the implementation of a multitest algorithm that uses GDH assays to screen for *C. difficile* in stool specimens, followed by either, CCCNA and/or TC to identify toxin-producing *C. difficile* strains. However, these procedures are not so useful in the clinical setting due to slow time to results, labor-intensity and need for special laboratory facilities. GDH assays have high sensitivity and NPV, but cannot differentiate between toxigenic and non-toxigenic strains. Therefore, they must be used sequentially with toxin confirmatory testing. Tox A/B EIAs that could be used alone or in combination with GDH are fast and specific

for toxin detection, but limited because of their low sensitivity. PCR-based toxin gene testing is also fast; however, their usefulness in the diagnosis of CDI is controversial^{12,15}.

Thus, the best testing strategy to diagnose CDI in the clinical laboratory to provide timely, cost-effective, and accurate results remains a subject of controversy. It is important to take into account that, in this study, the sensitivity of the assays was determined by comparing the results to those of CCCNA/CCCNA-TC. Since TC has better sensitivity than the CCCNA for detecting toxigenic *C. difficile* strains, it is not surprising that the sensitivities reported by others when comparing the assays to the gold standard (TC) are lower than those reported with CCCNA as the reference method^{15,19}.

Glutamate dehydrogenase

GDH, encoded by the *gluD* gene, is a metabolic enzyme produced by both toxigenic and nontoxigenic *C. difficile* strains and other *Clostridium* spp.; thus, its diagnostic utility is as a screening marker¹⁰. In the present study, the detection of GDH had the highest sensitivity (91.59%). The NLR of the GDH was 0.11, that is low enough to indicate that a negative result would rule out the CDI. However, it had the lowest specificity (76.92%) and PLR (3.97), indicating that a positive result should always be complemented with the detection of toxins or their encoding genes. Moreover, many reports point out differences in GDH assay sensitivities; indeed, this approach remains an interim recommendation in the Society for Healthcare Epidemiology of America (SHEA) Guidelines¹². Although our study and early studies comparing the GDH assay to CCCNA demonstrated high sensitivity and negative predictive values and concluded that the test for GDH is excellent for screening, more recent comparisons to TC and PCR have shown a sensitivity of 71–88%, which puts into question the value of these algorithms^{11,48,49}. These different sensitivities might be possibly due to regional/geographical differences in strain ribotypes but also to different detection methods that could affect the GDH assays^{12,27}. In this study, we demonstrated an 8.41% rate of false negatives, showing a good test performance.

Enzyme immunoassays

In the present study, RAB and QAB showed the lowest sensitivity – 52.94% and 58.88%, respectively; and the highest specificity – 96.62 and 94.41, respectively. These results agree with those reported by others^{2,21,25}. As noted, the RAB performance was comparable to that of the QAB with a slight decrease in the sensitivity test and a slight increase in the specificity test. Our data demonstrated that the addition of the EIA toxin detection on *C. difficile* isolates from direct toxin-negative stools (QAB-TC and RAB-TC), improved the sensitivity of the EIA kits of each single test (QAB and RAB). Indeed, the RAB/RAB-TC and the QAB/QAB-TC were the best toxigenic *C. difficile* detection methods evaluated, with sensitivity, specificity, PLR and NLR of 74.53%, 95.07%, 15.12, 0.27 and 78.30%, 94.41%, 14 and 0.23, respectively. Their good PLRs indicate that patients with CDI have a very

high chance to show positive tests compared with non-CDI subjects.

Polymerase chain reaction

Although the PCR assay seems to be rapid, sensitive and specific, its routine use is not recommended until more data are available¹².

In this study, we compared a PCR and a PCR/PCR-TC assay to detect the *tcdB* gene against CCCNA/CCCNA-TC. Ours results demonstrated that PCR assays may serve as suitable methods only for excluding but not for confirming CDI, conversely to those reported by Deshpande et al. in their meta-analysis on PCR assay performances, with overall means of sensitivity, specificity, PLR, and NLR of about 90%, 96%, 26.89 and 0.11, respectively¹⁵. The low specificity and PLR shown in this study are clinically undesirable for a diagnostic assay, because a false positive result may lead to unnecessary antimicrobial treatment and isolation of the patient¹⁹.

Several factors could have contributed to the differences observed in the results from the literature. It is possible that inter-study differences in performing the techniques used have occurred. It is important to take into account that most published data were obtained with real-time PCR assays instead of with a conventional PCR assay. Unlike conventional PCR, real-time PCR is more sensitive and has better resolution. Moreover, since there is no accepted real gold standard, CCCNA or TC are often used as reference tests¹⁵. Thus, it is possible that the use of a different reference standard – a combination of CCCNA and CCCNA-TC – could lead to an underestimation of the sensitivities and specificities obtained. This study reinforces the concept that non-commercial molecular methods can only be used for diagnostic purposes once validated by the reference method.

There are some potential limitations of using PCR as a diagnostic tool. It detects the *tcdB* gene encoding the toxin and not the toxin itself. Therefore, it might detect colonization instead of infection^{31,66}. In fact, other authors have reported that reliance on molecular testing instead on toxin testing can result in overdiagnosis and overtreatment of CDI^{17,51}. In view of these observations, it seems prudent not to recommend the PCR assay until more data are available regarding the diagnosis of CDI, outcome, and response to specific antimicrobial therapy.

It seems interesting to comment that diarrhea has many causes in hospitalized patients, where many of whom could be colonized with *C. difficile* strains, especially if they were staying in long-term care facilities, where *C. difficile* is the cause of diarrhea in 5% up to 30% of hospitalized patients who have diarrhea and are tested for *C. difficile*^{12,42}.

While a diagnostic assay may indicate the presence or absence of the organism or its toxins, the test by itself does not determine who does or does not have CDI. Thus, it is important to use test methods that can help in this matter because an accurate clinical diagnostic is mandatory^{17,18,52,53}. Moreover, it should be remembered that the diagnosis of CDI could be missed in patients whose stools are screened only for the presence of toxins^{5,29,34,40,41,65}.

In summary, despite the presence of toxigenic *C. difficile*, approximately 6% of samples may be negative by all the methods. When the rest of the tests are negative, the GDH, and PCR may be the only positive assays (5.6% and 0.9%, respectively). The GDH assay appeared to be a good screening test to rule out negative specimens and to select the samples for further testing. The GDH-positive stools must be confirmed using toxin tests to distinguish between toxigenic and nontoxigenic strains. Depending on the available possibilities of the laboratory and in view of the results, an appropriate strategy could be the use of TOX A/B EIAs in stools, followed by culture plus toxin detection from the isolates by EIAs, PCR or CCCNA, in the case of toxin-negative direct results.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this investigation.

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors declare that no patient data appears in this article.

Conflict of interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors acknowledge to MEDICA-TEC SRL and BIOARS SA from Ciudad Autónoma de Buenos Aires, Argentina, for kindly supply the commercially *C. difficile* toxin detection kits needed for the study.

References

1. Acosta MV, Greco GS, Nardi MA, Barcán L, Staneloni MI, Callejo R, De Cristofano MA, Oyamburu JM. Presentación de un caso clínico de infección por *Clostridium difficile* presuntamente B1/NAP1/027 en un hospital de comunidad. XIII Congreso Argentino de Microbiología, Resumen P-086. Rev Argent Microbiol. 2013;45 Suppl. 1:40.
2. Alcalá L, Sánchez-Cambronero L, Catalán MP, Sánchez-Somolinos M, Peláez MT, Marín M, Bouza E. Comparison of three commercial methods for rapid detection of *Clostridium difficile* toxins A and B from fecal specimens. J Clin Microbiol. 2008;46:3833–5.
3. Asensio A, Monge D. Epidemiology of *Clostridium difficile* infection in Spain. Enferm Infecc Microbiol Clin. 2012;30:333–7.
4. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of *Clostridium difficile* in adults: a systematic review. JAMA. 2015;313:398–408.
5. Barbut F, Lalande V, Burghoffer B, Thien HV, Grimprel E, Petit JC. Prevalence and genetic characterization of toxin A variant strains of *Clostridium difficile* among adults and children with diarrhea in France. J Clin Microbiol. 2002;40:2079–83.
6. Bartsch SM, Umscheid CA, Nachamkin I, Hamilton K, Lee BY. Comparing the economic and health benefits of different approaches to diagnosing *Clostridium difficile* infection. Clin Microbiol Infect. 2015;21:77.e1–9.
7. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ. *Clostridium difficile* infection in Europe: a hospital-based survey. Lancet. 2011;377:63–73.
8. Burnham CA, Carroll KC. Diagnosis of *Clostridium difficile* infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev. 2013;26:604–30.
9. Callejo R, Rollet R, Hardie N, Couto E. *Clostridium difficile* associated diarrhoea in HIV-AIDS hospitalized patients. Anaerobe 2000. An International Congress of the Confederation of Anaerobe Societies. Abstract Book VIII P2, Manchester, Inglaterra; 2000. p. 168.
10. Carman RJ, Wickham KN, Chen L, Lawrence AM, Boone JH, Wilkins TD, Kerkering TM, Lyerly DM. Glutamate dehydrogenase is highly conserved among *Clostridium difficile* ribotypes. J Clin Microbiol. 2012;50:1425–6.
11. Carroll KC, Loeffelholz M. Conventional versus molecular methods for the detection of *Clostridium difficile*. J Clin Microbiol. 2011;49 Suppl. 9:49–52.
12. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–55.
13. Dalpke AH, Hofko M, Zorn M, Zimmermann S. Evaluation of the fully automated BD MAX Cdiff and Xpert *C. difficile* assays for direct detection of *Clostridium difficile* in stool specimens. J Clin Microbiol. 2013;51:1906–8.
14. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for *Clostridium difficile* infection. Clin Microbiol Infect. 2014;20 Suppl. 2:1–26.
15. Deshpande A, Pasupuleti V, Rolston DD, Jain A, Deshpande N, Pant C, Hernandez AV. Diagnostic accuracy of real-time polymerase chain reaction in detection of *Clostridium difficile* in the stool samples of patients with suspected *Clostridium difficile* infection: a meta-analysis. Clin Infect Dis. 2011;53:e81–90.
16. Du P, Cao B, Wang J, Li W, Jia H, Zhang W, Lu J, Li Z, Yu H, Chen C, Cheng Y. Sequence variation in *tcdA* and *tcdB* of *Clostridium difficile*: ST37 with truncated *tcdA* is a potential epidemic strain in China. J Clin Microbiol. 2014;52:3264–70.
17. Dubberke ER, Burnham CA. Diagnosis of *Clostridium difficile* infection: treat the patient, not the test. JAMA Intern Med. 2015;175:1801–2.
18. Dubberke ER, Han Z, Bobo L, Hink T, Lawrence B, Copper S, Hoppe-Bauer J, Burnham CA, Dunne WM Jr. Impact of clinical symptoms on interpretation of diagnostic assays for *Clostridium difficile* infections. J Clin Microbiol. 2011;49:2887–93.
19. Eastwood K, Else P, Charlett A, Wilcox M. Comparison of nine commercially available *Clostridium difficile* toxin detection assays, a real-time PCR assay for *C. difficile tcdB*, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol. 2009;47:3211–7.
20. Erb S, Frei R, Stranden AM, Dangel M, Tschudin-Sutter S, Widmer AF. Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of *Clostridium difficile* infection in immunocompromised patients. Clin Microbiol Infect. 2015;21:998.e9–15.
21. Fenner L, Widmer AF, Goy G, Rudin S, Frei R. Rapid and reliable diagnostic algorithm for detection of *Clostridium difficile*. J Clin Microbiol. 2008;46:328–30.
22. Fernández Canigia L, Nazar J, Arce M, Dadamio J, Smayevsky J, Bianchini H. *Clostridium difficile* diarrhea: frequency of

- detection in a medical center in Buenos Aires, Argentina. *Rev Argent Microbiol.* 2001;33:101-7.
23. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH. The changing epidemiology of *Clostridium difficile* infections. *Clin Microbiol Rev.* 2010;23:529-49.
 24. Gilbreath JJ, Verma P, Abbott AN, Butler-Wu SM. Comparison of the Verigene *Clostridium difficile*, Simplexa *C. difficile* Universal Direct, BD MAX Cdiff, and Xpert *C. difficile* assays for the detection of toxigenic *C. difficile*. *Diagn Microbiol Infect Dis.* 2014;80:13-8.
 25. Gilligan PH. Is a two-step glutamate dehydrogenase antigen-cytotoxicity neutralization assay algorithm superior to the premier toxin A and B enzyme immunoassay for laboratory detection of *Clostridium difficile*? *J Clin Microbiol.* 2008;46:1523-5.
 26. Goldenberg SD, Cliff PR, French GL. Glutamate dehydrogenase for laboratory diagnosis of *Clostridium difficile* infection. *J Clin Microbiol.* 2010;48:3050-1, author reply 3051.
 27. Goldenberg SD, Gumban M, Hall A, Patel A, French GL. Lack of effect of strain type on detection of toxigenic *Clostridium difficile* by glutamate dehydrogenase and polymerase chain reaction. *Diagn Microbiol Infect Dis.* 2011;70:417-9.
 28. Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, Notermans DW, Bergwerff AA, Dekker FW, Kuijper EJ. Emergence of *Clostridium difficile* infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. *Clin Infect Dis.* 2008;47:1162-70.
 29. Goorhuis A, Legaria MC, van den Berg RJ, Harmanus C, Klaassen CH, Brazier JS, Lumelsky G, Kuijper EJ. Application of multiple-locus variable-number tandem-repeat analysis to determine clonal spread of toxin A-negative *Clostridium difficile* in a general hospital in Buenos Aires, Argentina. *Clin Microbiol Infect.* 2009;15:1080-6.
 30. Jamal W, Pauline E, Rotimi V. A prospective study of community-associated *Clostridium difficile* infection in Kuwait: epidemiology and ribotypes. *Anaerobe.* 2015;35:28-32.
 31. Jangi S, Lamont JT. Asymptomatic colonization by *Clostridium difficile* in infants: implications for disease in later life. *J Pediatr Gastroenterol Nutr.* 2010;51:2-7.
 32. Kato H, Kato N, Watanabe K, Iwai N, Nakamura H, Yamamoto T, Suzuki K, Kim SM, Chong Y, Wasito EB. Identification of toxin A-negative, toxin B-positive *Clostridium difficile* by PCR. *J Clin Microbiol.* 1998;36:2178-82.
 33. Kato N, Ou CY, Kato H, Bartley SL, Brown VK, Dowell VR Jr, Ueno K. Identification of toxigenic *Clostridium difficile* by the polymerase chain reaction. *J Clin Microbiol.* 1991;29:33-7.
 34. Kim H, Riley TV, Kim M, Kim CK, Yong D, Lee K, Chong Y, Park JW. Increasing prevalence of toxin A-negative, toxin B-positive isolates of *Clostridium difficile* in Korea: impact on laboratory diagnosis. *J Clin Microbiol.* 2008;46:1116-7.
 35. Korman TM. Diagnosis and management of *Clostridium difficile* infection. *Semin Respir Crit Care Med.* 2015;36:31-43.
 36. Legaria MC, Anchart EG, Rollet R, Di Martino A, Castello L, Barberis C, Rossetti A, Guardati MC, Fernández-Canigia L, Carloni G, Litterio M, Rocchi M, Cicchino M, Diaz M, Klajn D, Predari SC. Utilidad de la PCR para el diagnóstico de la infección causada por *Clostridium difficile*. Diferencias obtenidas según los cebadores utilizados. XIII Congreso Argentino de Microbiología. Resumen P345. *Rev Argent Microbiol.* 2013;45 Suppl. 1:139.
 37. Legaria MC, Lumelsky G, Greco G, De Cristóforo MA, Rosetti S. Alta prevalencia de *Clostridium difficile* (CD) toxina A negativa toxina B positiva en pacientes con diarrea asociada a CD (DACD) en un Hospital General. Reunión Científica. Microbiología Clínica. SADEBAC-AAM, Ciudad Autónoma de Buenos Aires, Argentina; 2003.
 38. Legaria MC, Lumelsky G, Rosetti S. *Clostridium difficile*-associated diarrhea from a general hospital in Argentina. *Anaerobe.* 2003;9:113-6.
 39. Legaria MC, Lumelsky G, Rosetti S, Brazier JS, Gal M. Typing and susceptibility study on *Clostridium difficile* from a general hospital in Argentina. The 6th Biennial Congress of the Anaerobe Society of the Americas, PII-35, Park City, Utah, USA; 2002.
 40. Legaria MC, Lumelsky G, Rosetti S, Greco G, Brazier JS, Gal M. Prevalence of toxin A-negative/B-positive *Clostridium difficile* in patients with gastrointestinal disease from a general hospital in Argentina. 7th Biennial Congress of the Anaerobe Society of the Americas, PI-18. *Anaerobe.* 2005;11:28-9.
 41. Legaria MC, Lumelsky G, van den Berg RJ, van der Vorm ER, Brazier JS, Kuijper EJ. Recognition of TcdA-negative *Clostridium difficile* as an important cause of hospital-acquired diarrhea in a general hospital in Argentina. The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2005, ICAAC K-1273-2005, Washington, DC, USA; 2005.
 42. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. Burden of *Clostridium difficile* infection in the United States. *N Engl J Med.* 2015;372:825-34.
 43. Litterio M, Roldán C, Rosanova M, Berberian G, Lopardo H. Diarrea asociada a *Clostridium difficile*. Experiencia en un hospital pediátrico. XI Congreso Argentino de Microbiología - Asociación Argentina de Microbiología, Resumen P-20721, Córdoba, Argentina; 2007.
 44. Lopardo G, Morfin-Otero R, Moran V, Noriega I.I. F, Zambrano B, Luxemburger C, Foglia G, Rivas EE. Epidemiology of *Clostridium difficile*: a hospital-based descriptive study in Argentina and Mexico. *Braz J Infect Dis.* 2015;19:8-14.
 45. Lyerly DM, Sullivan NM, Wilkins TD. Enzyme-linked immunosorbent assay for *Clostridium difficile* toxin A. *J Clin Microbiol.* 1983;17:72-8.
 46. Massey V, Gregson DB, Chagla AH, Storey M, John MA, Hussain Z. Clinical usefulness of components of the Triage immunoassay, enzyme immunoassay for toxins A and B, and cytotoxin B tissue culture assay for the diagnosis of *Clostridium difficile* diarrhea. *Am J Clin Pathol.* 2003;119:45-9.
 47. Mori N, Yoshizawa S, Saga T, Ishii Y, Murakami H, Iwata M, Collins DA, Riley TV, Tateda K. Incorrect diagnosis of *Clostridium difficile* infection in a university hospital in Japan. *J Infect Chemother.* 2015;21:718-22.
 48. Peterson LR, Manson RU, Paule SM, Hacek DM, Robicsek A, Thomson RB Jr, Kaul KL. Detection of toxigenic *Clostridium difficile* in stool samples by real-time polymerase chain reaction for the diagnosis of *C. difficile*-associated diarrhea. *Clin Infect Dis.* 2007;45:1152-60.
 49. Peterson LR, Mehta MS, Patel PA, Hacek DM, Harazin M, Nagwekar PP, Thomson RB Jr, Robicsek A. Laboratory testing for *Clostridium difficile* infection: light at the end of the tunnel. *Am J Clin Pathol.* 2011;136:372-80.
 50. Peterson LR, Robicsek A. Does my patient have *Clostridium difficile* infection. *Ann Intern Med.* 2009;151:176-9.
 51. Planche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA, O'Connor L, Oakley SJ, Pope CF, Wren MW, Shetty NP, Crook DW, Wilcox MH. Differences in outcome according to *Clostridium difficile* testing method: a prospective multicentre diagnostic validation study of *C. difficile* infection. *Lancet Infect Dis.* 2013;13:936-45.
 52. Polage CR, Gyorke CE, Kennedy MA, Leslie JL, Chin DL, Wang S, Nguyen HH, Huang B, Tang YW, Lee LW, Kim K, Taylor S, Romano PS, Panacek EA, Goodell PB, Solnick JV, Cohen SH. Overdiagnosis of *Clostridium difficile* infection in the molecular test era. *JAMA Intern Med.* 2015;175:1792-801.

53. Polage CR, Turkiewicz JV, Cohen SH. The never-ending struggle with laboratory testing for *Clostridium difficile* infection. *J Comp Eff Res*. 2016;5:113–6.
54. Poutanen SM, Simor AE. *Clostridium difficile*-associated diarrhea in adults. *CMAJ*. 2004;171:51–8.
55. Reigadas E, Alcalá L, Marín M, Burillo A, Muñoz P, Bouza E. Missed diagnosis of *Clostridium difficile* infection; a prospective evaluation of unselected stool samples. *J Infect*. 2015;70:264–72.
56. Rollet R, Meo A, Mirayes I, Brotto C, Badia M, Vázquez M, Garbasz C, Pereda R, Ballester D, Rodríguez L, Alfonso C, Perrone MC, Lovob L, Buccar, Cervetto M, Chavez ML, Gallego MJ, Manganello S, Minervini P, Rossetti S, Sokol M, Kaufman S, Grupo de Trabajo. Diarrea asociada a *Clostridium difficile* en hospitales del Gobierno de la Ciudad, un estudio multicéntrico. XIII Congreso Argentino de Microbiología. *Rev Argent Microbiol*. 2013;45 Suppl. 1:139.
57. Rollet R, Meol Mirayes A, Alfonso C, Perrone MC, Ballester D, Garbasz C, Lobov L, Manganello S, Kaufman S, Grupo de Trabajo. Estudio multicéntrico de diarrea asociada a *Clostridium difficile* en hospitales del Gobierno de la Ciudad Autónoma de Buenos Aires. XV Congreso Argentino de la Sociedad Argentina de Infectología, SADI 2015, Resumen ABS-575. Ciudad Autónoma de Buenos Aires, Argentina; 2015.
58. Rollet R, Vaustat D, Callejo R, Cabrera R, Hardie N. Glutamato deshidrogenasa su valor diagnóstico en la diarrea por *Clostridium difficile* VII Congreso de la Sociedad Argentina de Bacteriología, Micología y Parasitología Clínicas. SADEBAC - AAM. *Rev Argent Microbiol*. 2012;44 Suppl. 1:42–3.
59. Sharp SE, Ruden LO, Pohl JC, Hatcher PA, Jayne LM, Ivie WM. Evaluation of the C. Diff Quik Chek Complete Assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple diagnosis of *Clostridium difficile* disease. *J Clin Microbiol*. 2010;48:2082–6.
60. Shetty N, Wren MW, Coen PG. The role of glutamate dehydrogenase for the detection of *Clostridium difficile* in faecal samples: a meta-analysis. *J Hosp Infect*. 2011;77:1–6.
61. Stevens D, Byrant A, Berger A, von Eichel-Streiber C. *Clostridium*, vol. 1, 10th ed. Washington, DC, USA: ASM Press; 2011.
62. Ticehurst JR, Aird DZ, Dam LM, Borek AP, Hargrove JT, Carroll KC. Effective detection of toxigenic *Clostridium difficile* by a two-step algorithm including tests for antigen and cytotoxin. *J Clin Microbiol*. 2006;44:1145–9.
63. Trejo FM, Rusconi ME, Guzzetti L, Zamboni MI, Guardati MC, Lejona S, Pérez PF. Comparison of diagnostic methods for *Clostridium difficile*-associated diarrhea. *Rev Argent Microbiol*. 2010;42:165–71.
64. van den Berg RJ, Claas EC, Oyib DH, Klaassen CH, Dijkshoorn L, Brazier JS, Kuijper EJ. Characterization of toxin A-negative, toxin B-positive *Clostridium difficile* isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. *J Clin Microbiol*. 2004;42:1035–41.
65. van den Berg RJ, Legaria MC, de Breij A, Van der Vorm ER, Brazier JS, Kuijper EJ. Introduction and setting of toxin A negative *Clostridium difficile* in a general hospital in Argentina. 15th European Congress of Clinical Microbiology and Infectious Diseases. Abstract P1504. *Clin Microbiol Infect*. 2005;11 Suppl. 2:488.
66. Viscidi R, Willey S, Bartlett JG. Isolation rates and toxigenic potential of *Clostridium difficile* isolates from various patient populations. *Gastroenterology*. 1981;81:5–9.
67. Wilkins TD, Lyerly DM. *Clostridium difficile* testing: after 20 years, still challenging. *J Clin Microbiol*. 2003;41:531–4.
68. Zanella Terrier MC, Simonet ML, Bichard P, Frossard JL. Recurrent *Clostridium difficile* infections: the importance of the intestinal microbiota. *World J Gastroenterol*. 2014;20:7416–23.